Status:
RECRUITING
Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers
Lead Sponsor:
Hopital Foch
Conditions:
Muscle-Invasive Bladder Carcinoma
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this study is to demonstrate a significant gain in sensitivity versus surgical curage (extended pelvic) for initial lymph node staging of late FDG-PET images (2.5 hours) versus standard im...
Eligibility Criteria
Inclusion
- Patient 18 years of age or older,
- With histologically proven muscle-invasive bladder cancer (≥pT2) at endoscopic bladder resection,
- Scheduled to undergo 18FDG PET-CT in the nuclear medicine department at Hôpital Foch,
- Having signed a consent form,
- Affiliated to a health insurance scheme.
Exclusion
- Patient with a history of pelvic or genitourinary cancer,
- Patient with known metastatic disease,
- Patient with a contraindication to 18FDG PET-CT,
- Pregnant or breast-feeding woman,
- Patient deprived of liberty or under guardianship.
Key Trial Info
Start Date :
December 14 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 15 2027
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT06537960
Start Date
December 14 2023
End Date
March 15 2027
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Foch
Suresnes, Île-de-France Region, France, 92150